Overall, Wall Street analysts have a Hold consensus rating on HIMS stock based on five Buys, six Holds, and two Sells. The average HIMS stock price target of $45.92 implies a 56.3% upside potential.

You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed. Shares of the digital healthcare platform ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug ...